Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review by Mercadante, S. et al.
Vol. 33 No. 2 February 2007 Journal of Pain and Symptom Management 217Review Article
Medical Treatment for Inoperable Malignant
Bowel Obstruction: A Qualitative
Systematic Review
Sebastiano Mercadante, MD, Alessandra Casuccio, BS,
and Salvatore Mangione, MD
Pain Relief & Palliative Care Unit (S.Me.), La Maddalena Cancer Center; and Departments of
Anesthesiology, Intensive Care and Emergency Medicine (S.Me., S.Ma.), and Ophthalmology (A.C.),
University of Palermo, Palermo, Italy
Abstract
The use of symptomatic agents has greatly improved the medical treatment of advanced
cancer patients with inoperable bowel obstruction. A systematic review of studies of the most
popular drugs used in the medical management of inoperable malignant bowel obstruction
was performed to assess the effectiveness of these treatments and provide some lines of
evidence. Randomized trials that involved patients with a clinical diagnosis of intestinal
obstruction due to advanced cancer treated with these drugs were reviewed. Five reports
fulfilled inclusion criteria. Three studies compared octreotide (OC) and hyoscine
butylbromide (HB), and two studies compared corticosteroids (CSs) and placebo. Globally, 52
patients received OC, 51 patients received HB, 37 patients received CSs, 15 patients received
placebo, and 37 patients received both placebo and CSs. On the basis of these few data, the
superiority of OC over HB in relieving gastrointestinal symptoms was evidenced in a total of
103 patients. The latter studies had samples more defined in terms of stage and inoperability,
and had a shorter survival in comparison with studies of CSs (less than 61 days, most of
them less than 20 days). Data on CSs are less convincing, due to the methodological
weakness of existing studies. This review confirms the difficulties in conducting randomized
controlled trials in this population. J Pain Symptom Manage 2007;33:217e223.
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Bowel obstruction is a well-recognized com-
plication in advanced cancer patients with ab-
dominal or pelvic malignancy. Although it
may develop at any time of the disease, it
more frequently occurs in the advanced stage,
with the highest incidence ranging from 5.5%
to 42% in ovarian carcinoma, and from 4.4%
to 24% in colorectal cancer.1 These figures
may underestimate the problem, as they derive0885-3924/07/$esee front matter
doi:10.1016/j.jpainsymman.2006.06.014
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veys, it was found that 3% of advanced cancer
patients had intestinal obstruction, although
bowel obstruction has been also reported to
occur in up to 15% of patients.1e3 These dis-
crepancies may be attributable to the admis-
sion criteria of the palliative care units, which
may admit only patients with severe physical
and psychosocial distress, or patients in an
advanced stage of disease.3
Most advanced cancer patients are inopera-
ble. If surgery is not appropriate or possible,
survival prognosis is generally poor. Although
the onset of malignant obstruction means
a short prognosis, the distressing gastrointesti-
nal symptoms can be relieved.4
The introduction of new symptomatic
agents has greatly improved the symptom
management of such advanced cancer patients.
Corticosteroids (CSs) have been advocated to
reduce peritumoral inflammatory edema and
improve intestinal transit, inducing both tem-
porary symptom relief and reduction in ob-
struction. Moreover, they are able to reduce
water and salt secretion in the lumen, and
thereby act as antisecretive agents. As CSs are
relatively inexpensive and well tolerated, this
class of drugs has been largely used in the pal-
liative care setting for relieving gastrointestinal
symptoms or resolving obstruction.5
Anticholinergics also have been traditionally
used as antisecretive drugs in combination
with analgesics and antiemetics, due to the
competitive inhibition of muscarinic receptors
at the smooth muscle level, resulting in an im-
pairment of ganglionic neural transmission in
the bowel wall. Hyoscine butylbromide (HB),
hyoscine hydrobromide, and glycopyrrolate
have been commonly used.
Although HB has been the first drug used in
the medical treatment of inoperable bowel
obstruction as an antisecretive drug,6 in the
last decade, somatostatin analogs, and particu-
larly octreotide (OC), have been increasingly
used to relieve gastrointestinal symptoms in
advanced cancer patients with inoperable ma-
lignant bowel obstruction. OC affects gastro-
intestinal function by reducing gastric and
intestinal secretion and bile flow by complex
endocrine mechanisms.7
The aim of this study was to systematically
review the studies of the most popular
drugs used in the medical management ofinoperable malignant bowel obstruction in at-
tempt to evaluate the effectiveness and provide
some lines of evidence.
Methods
Both published and unpublished reports
were sought from an extensive search of elec-
tronic databases, including MEDLINE,
PubMed, CancerLit, and Embase. A free-text
search method was used, including the follow-
ing words and their combinations: ‘‘intestinal
or bowel obstruction’’ and/or ‘‘corticoste-
roids’’ or ‘‘steroids’’ and/or ‘‘octreotide,’’
and/or ‘‘hyoscine butylbromide.’’ Hand
searching of relevant journals, and European
conference proceedings were also considered.
The references of all relevant reports and re-
view articles were searched for additional trials.
Any randomized trial that involved patients
with a clinical diagnosis of intestinal obstruc-
tion due to advanced cancer treated with these
drugs was considered. The quality of all the re-
search found was graded using criteria previ-
ously reported.8
Results
Five reports fulfilled inclusion criteria in
this systematic review (Table 1). A total of 102
patients were identified: 52 received OC, 51 pa-
tients received HB, 37 received CSs (methyl-
prednisolone at low and high doses), 15
patients received placebo, and 37 patients re-
ceived both placebo andCSs (dexamethasone).
Two studies were not blinded;9,10 three were
double-blind,11e13 one of which had a crossover
design with 5-day phases.13 Scarcity of retrieved
data precluded any formal meta-analysis.
Study Duration and Survival
Study duration differed among studies,
ranging from 3 to 10 days. One study, compar-
ing OC and HB, was extended up to the day
before death.11 In OC and HB studies, patients
receiving the study drugs mainly had a short
survival, ranging from 4 to 61 days.9,10 Study
medication did not influence survival, which
varied from a few days to more than 300
days.12 In studies of CSs, a longer survival was
recorded. In one study, about 25% of patients
survived for more than 90 days.12 In another
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Randomized Studies Focusing on the Medical Management of Malignant Bowel Obstruction
Author, year
Population, study design,
duration of study, survival Outcome measures Notes
Quality
scale
Hardy et al., 1998 39 patients (2 withdrawals)
RC DB CO
a)Dexamethasone 16 mgd5 days
b)Placebod5 days
10 days
75 days (median)
Resolution of bowel
obstruction
13 patients responded to CSs;
8 patients responded to
placebo; unpleasant perianal
sensation
3
Laval et al., 2000 58 patients (6 withdrawals)
RC DB
a)Placebo
b)Methylprednisolone 40 mg
c)Methylprednisolone 240 mg
3 days
41 days (median)
Resolution of bowel
obstruction
68% on CSs; 33% on placebo 3
Ripamonti et al., 2000 17 patients
RC
a)OC 0.3 mg
b)HB 60 mg
3 days
11 days (mean)
Gastric content,
tube removal, nausea,
pain, dry mouth,
thirst, dyspnea,
abdominal distension,
drowsiness
OC better
than HB; hydrated
patients had less
drowsiness and nausea
2
Mercadante et al., 2000 18 patients (3 withdrawals)
RC
a)OC 0.3 mg
b)HB 60 mg
3 days
2e37 days
Vomiting, nausea,
drowsiness,
pain, fluids
OC better
than HB for vomiting
and nausea
2
Mystakidou et al., 2002 68 patients
(15 withdrawals at day 6)
RC DB
a)OC 0.6-0.8 mg CHL 15e25 mg
b)HB 60 mg CHL 15e25 mg
3e6 days, before death
7e61 days
Vomiting, nausea, pain,
anorexia, fatigue
OC better
than HB for vomiting
and nausea; no differences
after 6 days
2
RC¼ randomized-controlled; CO¼ crossover; DB¼ double-blind; OC¼ octreotide; HB¼ hyoscine butylbromide; CHL¼ chlorpromazine.study, the median time from obstruction to
death was 2.5 months.13 Of interest, these stud-
ies focused on the resolution of bowel obstruc-
tion rather than on symptom control.
Population and Setting
All studies were conducted with adults aged
from 38 to 80 years. The population was de-
fined as patients with ‘‘inoperable malignant
bowel obstruction.’’ In one study, this defini-
tion was not clearly stated.13 Two studies of
OC and HB were performed in both oncolog-
ical ward and palliative home care settings, and
one was conducted in a palliative care unit.
Studies of CSs were performed in palliative
care units.12,13
Bowel Obstruction Diagnosis
Different primary tumors were causing
bowel obstruction. Diagnosis was mainly based
on clinical and radiological examinations, andinoperability was decided after surgical consul-
tation. Onset of symptoms was described in
three studies only.9,10,13 Possible levels of
bowel obstruction were also described in one
study.10
Description and Methodological Quality
of Studies
Five studies had similar entry criteria in
terms of population, although different out-
come measures were used; outcome measures
sometimes were not well described. OC was
compared with HB in three studies. Two of
these were multicenter, open-label, and ran-
domized studies, performed by two groups in
two different settings, and included patients
having a nasogastric tube or not, respectively.
The follow-up was 3 days. The quality score
of both studies was 2.9,10 The third study
was randomized and double-blind, and pa-
tients concurrently received chlorpromazine.
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day before death. The quality score was 3.11
These studies were published in the last 5 years
and were published in English. The former
studies were undertaken in Italy, the latter in
Greece.
Two studies examined the effects of CSs in
the management of inoperable intestinal ob-
struction. These studies were flawed by several
methodological limitations. In a multicenter
national French study, methylprednisolone in
low and high doses was compared with placebo
using a randomized, controlled, double-blind
design. Fifty-eight patients were recruited
from 12 palliative care units, out of the initial
31 centers. Fifty-two patients were analyzed.
Six patients left the study (three died). Pa-
tients were allowed to take several drugs, in-
cluding antiemetics, antisecretive drugs
(excluding somatostatin analogs), analgesics,
and parenteral fluids, which were well bal-
anced in the groups.12 Although the Oxford
quality score was 3, statistical methods were
not reported. The relation between dosage
and efficacy could not be determined because
of the small number of patients recruited.
In another study, two trials in different pe-
riods were performed to improve accrual.
Most patients were on chemotherapy. Given
that the second trial was started 6 years after,
it is likely that chemotherapy regimens signifi-
cantly changed, introducing a bias that may
have been reinforced by some minor modifica-
tions of the protocol in an attempt to improve
the recruitment. The crossover design, when
the primary outcome is the resolution of bowel
obstruction at Day 5, makes the evaluation
poorly appropriate.13 The Oxford quality score
was 3, but statistical methods were not attemp-
ted and only descriptive analysis was shown.
The study samples in the CS studies had longer
survival in comparison with the samples se-
lected for studies of OC and HB.
Outcomes
In the first study, performed in 17 patients
already having a nasogastric tube for a mean
of 4.3 days (range 1e12), the gastric content
was the principal outcome measure, after
which removal of the gastric tube was allowed
in the presence of minimal gastric content.10
Patients with upper bowel obstruction were
excluded and no other drugs were allowed,except for analgesics. Description was available
on an individual basis for each patient. OC and
HB doses were 0.3 mg/day and 60 mg/day,
respectively. Mean gastric secretions halved
within 24 hours in OC patients and were less
than 400 ml/day in the following 2 days. Pa-
tients were stratified by groups of hospitalized
patients receiving parenteral fluids (as paren-
teral nutrition) and oral fluids, and home
care patients receiving minimal amounts of
fluids orally. When considering this latter
group of 10 patients, OC was more effective
in decreasing gastric secretions, and tube re-
moval was possible more often and earlier
than in patients receiving HB. There was
a trend suggesting that hydration may
decrease drowsiness and nausea, but possibly
limiting the effects of antisecretive agents on
gastric secretions.
In the second study of 18 patients,9 the prin-
cipal outcome was symptom intensity: vomiting
episodes, nausea, drowsiness, dry mouth, and
pain. OC and HB doses were 0.3 mg/day and
60 mg/day, respectively. Analgesics and halo-
peridol 5 mg/day were allowed. OC was more
effective than HB in reducing vomiting epi-
sodes and nausea. Patients were stratified ac-
cording to the level of hydration provided in
the two settings of home care and oncological
ward. Lower levels of hydration were associated
with nausea regardless of the treatment.
In the third study, which recruited a higher
number of patients (n¼ 68),11 OC and HB
were given in doses of 0.6e0.8 mg/day and
80 mg/day, respectively, which are higher
than those used in previous studies.9,10 Patients
withhigh level of bowel obstructionwere also in-
cluded. Chlorpromazine 5e25 mg/day and an-
algesics were allowed in both groups, and no
hydration or parenteral nutrition was provided.
Vomiting, nausea, pain, fatigue, and anorexia
were monitored. Nausea and vomiting signifi-
cantly improved in the OC group in compar-
ison with the HB group 3 days after starting
the protocol (vomiting control: 91% with
OC vs. 64% with HB). However, at Day 6
and at the day before death (reported in
the abstract, from 7 to 61 days, no mean is
provided) differences were not significant.
This finding was attributed to patient dropout
(15 patients withdrew before Day 6). Mean
doses of opioids were lower with OC than
with HB.
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with placebo. The first study was a crossover
study, using 4 mg of dexamethasone every
6 hours for 5 days or saline intravenously. If
the obstruction resolved within 5 days, the
treatment was discontinued; otherwise, the pa-
tient was crossed over to the other arm for
a further 5-day period. Response was defined
as the resolution of the bowel obstruction.
The trial terminated and subsequently was re-
opened for further accrual. The overall re-
sponse rate was 60%, differing in patients
who concomitantly received chemotherapy or
not (70% and 47%, respectively). Response
was 62% with dexamethasone and 57% with
placebo. The median time from obstruction
to death was 2.5 months (range >1e18
months). The authors were unable to make
any conclusions as to the effectiveness of
dexamethasone.13
In a multicenter study of 58 patients ran-
domly treated with a low or high dose of CS
and placebo, 52 were available for analysis.
Twelve patients having a nasogastric tube
were not taken into consideration for analysis,
despite being included in the initial protocol.
In the remaining 40 patients, resolution of
bowel obstruction was obtained twice as often
as in the medicated group (including both
dose groups, low and high CS doses, respec-
tively) when compared to the control group.
Improvement of symptoms was not detailed,
as no definition or specific measures were in-
cluded. Moreover, timing of assessment and
duration of benefit were not described. The
definition of bowel obstruction was broad
and generic. Vomiting was present only in
62% of patients, including subjects with a naso-
gastric tube (23%). This means that fewer than
half of patients had vomiting. Survival was
quite extended, 25% of patients being alive
90 days after starting the treatment.9
Adverse Effects
Several patients receiving dexamethasone
complained of an unpleasant perianal sensa-
tion, and one patient was withdrawn because
of gastrointestinal toxicity.10 No other effects
could definitively be attributed to CSs.12 Minor
skin reactions were equally reported in pa-
tients received OC and HB plus chlorproma-
zine subcutaneously.11 No differences in drymouth were found between OC and HB
groups.9,10
Discussion
Conducting scientifically sound trials in this
population is a considerable challenge. The
small number of randomized published trials
reflects the difficulty of recruiting an adequate
number of patients from among terminally ill
cancer patients. We recognize that large
amounts of information are needed to over-
come random effects in estimating direction
and magnitude of treatment effects. To prove
or disapprove any effect from a treatment,
some hundreds of patients would have to be
randomized, but in the setting of advanced
cancer, subjects are often unwell, attrition
rate is high, and it is not unusual to fail to com-
plete studies because of clinical deterioration.
Moreover, staff members are often reluctant
to recruit dying patients to any more
experimentation.
This systematic review examined the effect
of the most common drugs used for the med-
ical management of gastrointestinal symptoms
due to malignant bowel obstruction. Only five
papers were relevant for a review of controlled
clinical trials.
The importance of study design needs to be
emphasized. The use of a placebo control may
potentially expose patients to unnecessary un-
relieved gastrointestinal symptoms, as most
drugs commonly used are considered to pro-
duce a benefit, despite lack of clear evidence.
A crossover design could amplify the effect,
but this approach is unlikely in an unstable
population with short survival, and the use of
a washout period would possibly be considered
unethical.
In a previous meta-analysis including any
kind of study regarding CSs, a trend in the ev-
idence that dexamethasone may bring about
the resolution of bowel obstruction was re-
ported.14 Some of these studies, previously la-
beled as gray literature, were finally published
and reviewed in the present analysis. CSs were
compared with placebo in two studies, which
showed a weak effect in relieving gastrointes-
tinal symptoms. These studies were flawed
by several methodological problems, regard-
less of the number of patients. In one study,
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tients were included and then excluded (pa-
tients with nasogastric tubes) from analysis,
many drugs able to relieve gastrointestinal
symptoms were allowed, timing of assessment
and outcome were uncertain, and data on dif-
ferent doses of methylprednisolone were
summed to be compared with placebo.12 In
the second one, the chances of resolution of
bowel obstruction were largely determined
by whether the patients were receiving che-
motherapy; the regimen was likely to be
changed during the long period that elapsed
between the two phases of study, the disease
stage was relatively early, and there was
a lack of definition of inoperability. The use
of a crossover design in such unstable pa-
tients, who may have a spontaneous resolu-
tion, is confounding.13 Survival was quite
extended when compared with other con-
trolled trials of OC and HB, 25% of patients
being alive 90 days after starting the treat-
ment,12 or having a mean survival of 75
days.13
Other studies have compared the effects of
antisecretive drugs, acting with different mech-
anisms.10e12 All these studies confirmed the
superiority of OC over HB in a total of 103 pa-
tients, a sample relatively large in this context.
Nausea and vomiting improved more with OC
than with HB, in studies with similar designs
and outcomes, at least on a short-term basis.
The study populations were more defined in
terms of stage and inoperability, and had
a shorter survival in comparison with CSs stud-
ied (less than 61 days, most of them less than
20 days). These groups seem to be more repre-
sentative of advanced cancer patients who are
often considered inoperable. No comparison
has been done between CSs and OC or HB.
Conclusion
Despite decades of experience since the first
proposal of medical management of gastroin-
testinal symptoms in inoperable advanced
cancer patients, few data are available from
randomized clinical trials. These data are com-
promised by several methodological flaws and
a low level of recruitment capacity, due to the
characteristics of such patients. Moreover, the
modern approach seems to be more directedtoward a multimodal treatment, including dif-
ferent agents, particularly drugs with relatively
low toxicities and different mechanisms of
action, which may synergistically or additively
improve gastrointestinal symptoms or partially
resolve bowel obstruction.14 On the basis of
data published in randomized trials, OC can
be reasonably considered more effective than
HB in relieving symptoms due to inoperable
bowel obstruction, while the role of CSs still re-
mains debatable and requires further studies
in a more selected population. More efforts
are needed in research, possibly promoting
multicenter studies, to establish the most cost-
effective treatment in this kind of population.
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